Erschienen in:
16.09.2016 | Melanomas
Editorial: Should We Abandon TNM Staging in Favor of Gene Profiles in Node-Positive Melanoma?
verfasst von:
Kathryn E. Engelhardt, MD, Jeffrey D. Wayne, MD, Karl Y. Bilimoria, MD, MS
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2017
Einloggen, um Zugang zu erhalten
Excerpt
Patients with sentinel lymph node (SLN)-positive stage III melanoma have heterogeneous outcomes ranging from 23 to 87 %.
1 Due to this variability, it is challenging to provide prognostic information to patients, stratify patients appropriately for clinical trials, and make decisions regarding adjuvant therapy. Thus, there would be value in identifying a gene signature that would allow discrimination of patients with stage III melanoma into high- and low-risk groups. …